Ironwood Pharmaceuticals (IRWD) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 144.9% versus a loss of 14.8%. Over five years, MNPR leads with a +242.1% price change compared with -71.7% for IRWD. Ironwood Pharmaceuticals is the larger company by market cap ($639.5 million vs $563.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRWD | MNPR |
|---|---|---|
| Share price | $3.87 | $83.98 |
| Market cap | $639.48M | $563.69M |
| 1-day change | +3.20% | +0.24% |
| YTD return | +14.84% | +28.61% |
| 1-year return | +144.94% | -14.80% |
| 5-year return | -71.67% | +242.08% |
| P/E ratio (TTM) | 5.03 | — |
| Forward P/E | 2.58 | — |
| EPS (TTM) | $0.77 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.78 | $124.82 |
| 52-week low | $1.41 | $50.07 |
| Distance from 52-week high | -33.04% | -32.72% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +57.62% | +54.70% |
| Average volume | 2.02M | 215.52K |
| Shares outstanding | 165.24M | 6.71M |
| Employees | 100 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed MNPR by 159.7 percentage points over the past year.
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
IRWD vs MNPR FAQ
Which is bigger, Ironwood Pharmaceuticals or Monopar Therapeutics?
Ironwood Pharmaceuticals (IRWD) is larger, with a market capitalization of $639.48M compared with $563.69M for Monopar Therapeutics (MNPR).
Which stock has performed better over the past year, IRWD or MNPR?
IRWD returned +144.94% over the past 12 months, compared with -14.80% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Ironwood Pharmaceuticals and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.